Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

By D. M. van der Heijde, A. Kivitz, M. Schiff, J. Sieper, B. Dijkmans, J. Braun, M. Dougados, J. Reveille, R. Wong, H. Kupper and 1 more. Arthritis & Rheumatism, 2006

847 citations recorded by the source corpus.

Subfields: Rheumatology

View Paper: https://www.semanticscholar.org/paper/c5bcdb2b52514f0e019a1e396e5b616cd18e32b5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Heijde
2. Jürgen Braun
3. J. Sieper
4. R. Burgos-Vargas
5. R. Berg
6. B. Dijkmans
7. P. Emery
8. W. Maksymowych

Citations in the corpus

• 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (2011, background): “there were many new studies. In addition to infliximab and etanercept, adalimumab”